Latest News

Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer
Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer

June 9th 2025

Satri-cel led to a median PFS of 3.25 months vs 1.77 months with physician’s choice in patients with pretreated gastric or gastroesophageal cancer.

Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC
Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

June 6th 2025

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC
THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

June 5th 2025

Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC
Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC

June 4th 2025

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC
Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

June 3rd 2025